Novocure touts analysis of pivotal glioblastoma trial results

This article was originally published here

NovocureNovocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma.

The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received just temozolomide.

Gte the full story at our sister site, Drug Delivery Business News.

The post Novocure touts analysis of pivotal glioblastoma trial results appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply